Genetically engineered biomimetic nanoparticles for targeted delivery of mRNA to treat rheumatoid arthritis
Publication in refereed journal

Altmetrics Information
.

Other information
AbstractIn addition to inhibiting persistent inflammation, phosphatase and tensin homolog deleted from chromosome 10 (PTEN) is known as an important therapeutic target for alleviating rheumatoid arthritis (RA) symptoms. Modulation of PTEN gene expression in synovial tissue using messenger RNA (mRNA) is a promising approach to combat RA. However, mRNA therapeutics are often hampered by unsatisfactory stability and inefficient localization in synovial tissue. In this study, a genetically engineered biomimetic membrane-coated mRNA (MR@P-mPTEN) carrier that effectively delivers mRNA-PTEN (mPTEN) directly to the RA joint is presented. By overexpressing tumor necrosis factor (TNF-α) receptors on macrophage biomimetic membranes via plasmid transfection, decoys that reduce inflammatory pathway activation are prepared for TNF-α. The resulting construct, MR@P-mPTEN, shows good stability and RA targeting based on in vivo fluorescence imaging. It is also found that MR@P-mPTEN competitively binds TNF-α and activates the PTEN pathway in vitro and in vivo, thereby inhibiting synovitis and joint damage. Clinical micro-computed tomography and histological analyses confirm the treatment effects. These results suggest that the genetically engineered biomimetic therapeutic platform MR@P-mPTEN both inhibits pro-inflammatory cytokines and upregulates PTEN protein expression to alleviate RA damage, providing a new a new combination strategy for RA treatment.
All Author(s) ListJianhai Chen, Jianwei Tan, Jian Li, Wenxiang Cheng, Liqing Ke, Anqiao Wang, Qiqing Wang, Sien Lin, Gang Li, Benguo Wang, Jingqin Chen, Peng Zhang
Journal nameSmall Methods
Year2023
Month11
Day16
Volume Number7
Issue Number11
PublisherJohn Wiley & Sons Ltd
Article number2300678
ISSN2366-9608
eISSN2366-9608
LanguagesEnglish-United States

Last updated on 2024-26-06 at 10:45